Hydroxyurea dosing for children with sickle cell anemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged between 6 months and 18 years.
- Diagnosis of sickle cell anemia (SS or SBThal0).
- Either new to hydroxyurea and willing to take it for 12 months, or already on hydroxyurea for over a year with a stable, effective dose.
- No blood transfusion in the last month, not on a chronic transfusion program, and no prior stem cell transplant.
- Normal kidney and liver function, not pregnant, and willing to use birth control if sexually active.
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
- fitModel.criteria_met placeholder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
This trial compares a new gene therapy to the standard care for people with severe sickle cell disease. It aims to see if the gene therapy is better at reducing painful crises and complications.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
This study looks at how people of Nigerian descent with sickle cell disease respond to hydroxyurea, a medicine that helps prevent painful episodes. The goal is to see how your genetic makeup affects how the drug works so that doctors can find the best dose for you.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
Hear when a new Sickle Cell Disease (SCD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.